Flagship Ventures Fund IV General Partner LLC's Net Worth

$4.97 Billion

Estimate Recalculated Jun 18, 2024 06:10PM EST

Who is Flagship Ventures Fund IV General Partner LLC?

Flagship Ventures Fund IV General Partner LLC has an estimated net worth of $4.97 Billion. This is based on reported shares across multiple companies, which include Moderna, Inc., Kaleido Biosciences, Inc., Seres Therapeutics, Inc., Editas Medicine, Inc., TransMedics Group, Inc., Rubius Therapeutics, Inc., Syros Pharmaceuticals, Inc., Eleven Biotherapeutics, Inc., T2 Biosystems, Inc., Axcella Health Inc., and Evelo Biosciences, Inc..

SEC CIK

Flagship Ventures Fund IV General Partner LLC's CIK is 0001508051

Past Insider Trading and Trends

2018 was Flagship Ventures Fund IV General Partner LLC's most active year for acquiring shares with 20 total transactions. Flagship Ventures Fund IV General Partner LLC's most active month to acquire stocks was the month of April. 2016 was Flagship Ventures Fund IV General Partner LLC's most active year for disposing of shares, totalling 47 transactions. Flagship Ventures Fund IV General Partner LLC's most active month to dispose stocks was the month of April. 2022 saw Flagship Ventures Fund IV General Partner LLC paying a total of $69,099,363.15 for 44,100,390 shares, this is the most they've acquired in one year. In 2020 Flagship Ventures Fund IV General Partner LLC cashed out on 32,241,407 shares for a total of $68,219,276.30, their largest year based on trade value.

Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!

Moderna, Inc. (MRNA) Snapshot price: $100.17

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
-36.29%
-11.05M
19.41M
Aug 17
Form 4
-1.71%
-1.00M
$68.22
-$68,219,276.30
57.31M
May 21 - May 22
Form 4
-29.46%
-12.28M
29.41M
May 11
Form 4
-5.75%
-9.67M
$18.87
-$8,196,935.61
158.57M
Dec 9 - Dec 11
Form 4
47.34M
47.34M
Dec 11
Form 3
0
0
No matching records found

Kaleido Biosciences, Inc. (KLDO) No price found

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
+4.14%
215K
$11.50
$2,472,500.00
5.41M
Feb 8
Form 4
+62.67%
2M
$7.50
$15,000,000.00
5.19M
Jun 4
Form 4
+158.12%
1.12M
1.83M
Mar 4
Form 3
0
0
No matching records found

Seres Therapeutics, Inc. (MCRB) Snapshot price: $1.11

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
-39.84%
-7.91M
11.94M
Nov 23
Form 4
-12.02%
-2.00M
$27.60
-$27,600,000.00
14.64M
May 25
Form 4
11.63M
11.63M
Jun 25 - Jun 26
Form 3
0
0
No matching records found

Editas Medicine, Inc. (EDIT) Snapshot price: $7.125

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
-30.97%
-1.55M
3.46M
Aug 11
Form 4
4.96M
4.96M
Feb 8
Form 3
0
0
No matching records found

TransMedics Group, Inc. (TMDX) Snapshot price: $88.39

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
-100.00%
-2.84M
0
Oct 29
Form 4
+49.67%
839.7K
2.53M
May 6
Form 3
0
0
No matching records found